DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer

相似書籍

• Quantification and Dynamic Monitoring of EGFR T790M in Plasma Cell-Free DNA by Digital PCR for Prognosis of EGFR-TKI Treatment in Advanced NSCLC
  由: Wang, Zhijie, et al.
  出版: (2014)
• Analysis of EGFR mutation status in tissue and plasma for predicting response to EGFR-TKIs in advanced non-small-cell lung cancer
  由: Wang, Yuyan, et al.
  出版: (2017)
• Patients harboring epidermal growth factor receptor (EGFR) double mutations had a lower objective response rate than those with a single mutation in non-small cell lung cancer when treated with EGFR-tyrosine kinase inhibitors
  由: Wei, Zhigang, et al.
  出版: (2014)
• Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation
  由: Wang, Shuhang, et al.
  出版: (2015)
• ERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations
  由: Wang, Zhijie, et al.
  出版: (2015)